Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Outdated health service IT ‘cost lives’ says health secretary

Matt Hancock outlines plan for a “tech-driven” NHS

Gilead Sciences

Gilead, Galapagos JAK inhibitor clears phase II test

Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly

HSJ Awards Finalists Announced

2018 HSJ Awards Finalists Announced.

Wilmington Healthcare

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results

- PMLiVE

Money, sex and power

What really makes your world go round? Is it money, sex or power? Or is it something more subtle?

Page & Page Health

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

- PMLiVE

The Creative Floor reveal finalists, Lucid’s Louise Verrall hosts pitch session and Star celebrates 16 years

Healthcare Comms news

- PMLiVE

Novartis’ CAR-T Kymriah gets green light in England

Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population

- PMLiVE

Ashfield, Health Unlimited and Ashley Communications add to their teams

The latest med comms movers

- PMLiVE

NICE U-turn on Crystiva for rare bone disease

Watchdog to back the drug to treat young people with XLH

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links